Literature DB >> 24901682

Transanal endoscopic surgery with total wall excision is required with rectal adenomas due to the high frequency of adenocarcinoma.

Xavier Serra-Aracil1, Aleidis Caro-Tarrago, Laura Mora-López, Alex Casalots, Pere Rebasa, Salvador Navarro-Soto.   

Abstract

BACKGROUND: Colorectal adenomatous polyps are considered premalignant lesions, although a high percentage are already malignant at the time of their removal. Full-thickness excision in patients with adenoma detected in preoperative biopsy enables much more accurate pathology examination and has shown that local surgery is appropriate for T1 adenocarcinoma.
OBJECTIVE: To determine whether full-thickness excision during transanal endoscopic surgery is the treatment of choice for rectal adenoma, and to identify possible predictors of invasive adenocarcinoma associated with this type of lesion.
DESIGN: Prospective, observational study.
SETTING: The study was conducted at a university teaching hospital. PATIENTS: All patients scheduled for transanal endoscopic surgery after detection of adenoma in a preoperative biopsy between June 2004 and February 2013 entered the study. MAIN OUTCOME MEASURES: The principal variable was the presence of invasive adenocarcinoma in the pathology study. Other study variables were the epidemiological variables sex and age; the clinical variables tumor size, number of quadrants affected, distance from the anal verge, and tumor location; and the morphological variables tumor aspect, degree of dysplasia, preoperative biopsy (tubulo-villous), endorectal ultrasound, and pelvic MRI stage. Variables found to be related to the risk of malignancy in rectal adenomas were evaluated using univariate and multivariate analysis.
RESULTS: Of 471 patients who underwent surgery, 277 had a preoperative diagnosis of adenoma. Final pathology studies showed 52 (18.8%) invasive adenocarcinomas, among which 27 were pT1 (52%), 16 pT2 (30.7%), and 9 pT3 (17.3%). Factors predictive of invasive adenocarcinoma were sessile morphology (OR 3.2, 95%CI 1.4-7.1), high-grade dysplasia (OR 2.3, 95%CI 1.2-4.8), and endorectal ultrasound stage uT2-T3 (OR 3.8, 95%CI 1.6-9). LIMITATIONS: The limitations are derived from the observational design.
CONCLUSIONS: In this sample, half of the adenocarcinomas from adenomas were T1 adenocarcinomas. Because a high proportion of rectal adenomas are, in fact, invasive adenocarcinomas, full-thickness excision is appropriate.

Entities:  

Mesh:

Year:  2014        PMID: 24901682     DOI: 10.1097/DCR.0000000000000139

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

1.  Histopathological and radiological reporting in rectal cancer: concepts and controversies, facts and fantasies.

Authors:  S Balyasnikova; N Haboubi; B Moran; G Brown
Journal:  Tech Coloproctol       Date:  2016-12-07       Impact factor: 3.781

2.  Hybrid NOTES: TEO for transanal total mesorectal excision: intracorporeal resection and anastomosis.

Authors:  Xavier Serra-Aracil; Laura Mora-López; Alex Casalots; Carles Pericay; Raul Guerrero; Salvador Navarro-Soto
Journal:  Surg Endosc       Date:  2015-03-27       Impact factor: 4.584

3.  Transanal endoscopic microsurgery in very large and ultra large rectal neoplasia.

Authors:  X Serra-Aracil; R Flores-Clotet; L Mora-López; A Pallisera-Lloveras; S Serra-Pla; S Navarro-Soto
Journal:  Tech Coloproctol       Date:  2019-08-28       Impact factor: 3.781

4.  Endorectal ultrasound in the identification of rectal tumors for transanal endoscopic surgery: factors influencing its accuracy.

Authors:  Xavier Serra-Aracil; Ana Gálvez; Laura Mora-López; Pere Rebasa; Sheila Serra-Pla; Anna Pallisera-Lloveras; Carla Zerpa; Oriol Moreno; Salvador Navarro-Soto
Journal:  Surg Endosc       Date:  2017-12-21       Impact factor: 4.584

Review 5.  Local excision by transanal endoscopic surgery.

Authors:  Luis J García-Flórez; Jorge L Otero-Díez
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

Review 6.  Transanal endoscopic surgery in rectal cancer.

Authors:  Xavier Serra-Aracil; Laura Mora-Lopez; Manel Alcantara-Moral; Aleidis Caro-Tarrago; Carlos Javier Gomez-Diaz; Salvador Navarro-Soto
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  Transanal endoscopic micro-surgery in elderly and very elderly patients: a safe option? Observational study with prospective data collection.

Authors:  X Serra-Aracil; S Serra-Pla; L Mora-Lopez; A Pallisera-Lloveras; M Labro-Ciurans; S Navarro-Soto
Journal:  Surg Endosc       Date:  2018-06-22       Impact factor: 4.584

8.  Importance of Resection Margins in the Treatment of Rectal Adenomas by Transanal Endoscopic Surgery.

Authors:  Xavier Serra-Aracil; Neus Ruiz-Edo; Alex Casalots-Casado; Laura Mora-López; Anna Pallisera-Lloveras; Sheila Serra-Pla; Vanlentí Puig-Diví; Salvador Navarro-Soto
Journal:  J Gastrointest Surg       Date:  2018-10-10       Impact factor: 3.452

9.  Completion total mesorectal excision following transanal endoscopic microsurgery does not compromise outcomes in patients with rectal cancer.

Authors:  Katarina Levic Souzani; Orhan Bulut; Tine Plato Kuhlmann; Ismail Gögenur; Thue Bisgaard
Journal:  Surg Endosc       Date:  2021-02-24       Impact factor: 4.584

Review 10.  International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.

Authors:  Emmanouil Fokas; Ane Appelt; Alexandra Gilbert; David Sebag-Montefiore; Claus Rödel; Robert Glynne-Jones; Geerard Beets; Rodrigo Perez; Julio Garcia-Aguilar; Eric Rullier; J Joshua Smith; Corrie Marijnen; Femke P Peters; Maxine van der Valk; Regina Beets-Tan; Arthur S Myint; Jean-Pierre Gerard; Simon P Bach; Michael Ghadimi; Ralf D Hofheinz; Krzysztof Bujko; Cihan Gani; Karin Haustermans; Bruce D Minsky; Ethan Ludmir; Nicholas P West; Maria A Gambacorta; Vincenzo Valentini; Marc Buyse; Andrew G Renehan
Journal:  Nat Rev Clin Oncol       Date:  2021-08-04       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.